Journal of Neurology

, Volume 255, Supplement 5, pp 18–32 | Cite as

Epidemiology of Parkinson’s disease

  • Guido Alves
  • Elin Bjelland Forsaa
  • Kenn Freddy Pedersen
  • Michaela Dreetz Gjerstad
  • Jan Petter Larsen
Article

Abstract

Epidemiological research aims to provide information on the development, prevalence and progression of diseases, and their associated risk factors. Epidemiological research is thus the basis of increasing our understanding on the aetiology of diseases and as a consequence the starting point for identifying at risk groups in the population, development for novel prevention and treatment strategies, and health care planning. This review provides an overview of the epidemiology of Parkinson’s disease, the second most common neurodegenerative disorder, with special emphasis on population-based data on the clinical progression of motor and non-motor features of the disease.

Key words

Parkinson’s disease epidemiology population-based progression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N Engl J Med 328:176–183Google Scholar
  2. 2.
    Adler CH, Thorpy MJ (2005) Sleep issues in Parkinson’s disease. Neurology 64:S12–S20PubMedCrossRefGoogle Scholar
  3. 3.
    Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458PubMedCrossRefGoogle Scholar
  4. 4.
    Allam MF, Del Castillo AS, Navajas RF (2005) Parkinson’s disease risk factors: genetic, environmental, or both? Neurol Res 27:206–208PubMedCrossRefGoogle Scholar
  5. 5.
    Allcock LM, Ullyart K, Kenny RA, Burn DJ (2004) Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1470–1471PubMedCrossRefGoogle Scholar
  6. 6.
    Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, Ferini-Strambi L (2005) Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165:1286–1292PubMedCrossRefGoogle Scholar
  7. 7.
    Alves G, Kurz M, Lie SA, Larsen JP (2004) Cigarette smoking in Parkinson’s disease: influence on disease progression. Mov Disord 19:1087–1092PubMedCrossRefGoogle Scholar
  8. 8.
    Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D (2006) Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 21:1123–1130PubMedCrossRefGoogle Scholar
  9. 9.
    Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 63:1908–1911PubMedGoogle Scholar
  10. 10.
    Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2005) Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 65:1436–1441PubMedCrossRefGoogle Scholar
  11. 11.
    Autere JM, Moilanen JS, Myllyla VV, Majamaa K (2000) Familial aggregation of Parkinson’s disease in a Finnish population. J Neurol Neurosurg Psychiatry 69:107–109PubMedCrossRefGoogle Scholar
  12. 12.
    Beyer MK, Herlofson K, Arsland D, Larsen JP (2001) Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 103:7–11PubMedCrossRefGoogle Scholar
  13. 13.
    Bhidayasiri R, Truong DD (2008) Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 266:204–215PubMedCrossRefGoogle Scholar
  14. 14.
    Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16:622–630PubMedCrossRefGoogle Scholar
  15. 15.
    Boeve BF, Silber MH, Parisi JE, Dickson DW, Ferman TJ, Benarroch EE, Schmeichel AM, Smith GE, Petersen RC, Ahlskog JE, Matsumoto JY, Knopman DS, Schenck CH, Mahowald MW (2003) Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 61:40–45PubMedGoogle Scholar
  16. 16.
    Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, Rossi G, Piaggesi A (2003) Orthostatic hypotension in de novo Parkinson disease. Arch Neurol 60:1400–1404PubMedCrossRefGoogle Scholar
  17. 17.
    Braga-Neto P, da Silva-Junior FP, Sueli Monte F, de Bruin PF, de Bruin VM (2004) Snoring and excessive daytime sleepiness in Parkinson’s disease. J Neurol Sci 217:41–45PubMedCrossRefGoogle Scholar
  18. 18.
    Bronnick K, Emre M, Lane R, Tekin S, Aarsland D (2007) Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 78:1064–1068PubMedCrossRefGoogle Scholar
  19. 19.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRefGoogle Scholar
  20. 20.
    Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMedGoogle Scholar
  21. 21.
    Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG (2006) Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77:585–589PubMedCrossRefGoogle Scholar
  22. 22.
    Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70:1017–1022PubMedCrossRefGoogle Scholar
  23. 23.
    Cairns V, Godwin J (2005) Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 34:1340–1345PubMedCrossRefGoogle Scholar
  24. 24.
    Chaudhuri A, Behan PO (2004) Fatigue in neurological disorders. Lancet 363:978–988PubMedCrossRefGoogle Scholar
  25. 25.
    Coleman RM, Pollak CP, Weitzman ED (1980) Periodic movements in sleep (nocturnal myoclonus): relation to sleep disorders. Ann Neurol 8:416–421PubMedCrossRefGoogle Scholar
  26. 26.
    Comella CL, Nardine TM, Diederich NJ, Stebbins GT (1998) Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology 51:526–529PubMedGoogle Scholar
  27. 27.
    de Maindreville AD, Fenelon G, Mahieux F (2005) Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord 20:212–217PubMedCrossRefGoogle Scholar
  28. 28.
    Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI (1992) Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:138–142PubMedCrossRefGoogle Scholar
  29. 29.
    Dubois B, Pillon B (1997) Cognitive deficits in Parkinson’s disease. J Neurol 244:2–8PubMedCrossRefGoogle Scholar
  30. 30.
    Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, Rocca WA (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60:91–96PubMedCrossRefGoogle Scholar
  31. 31.
    Elbaz A, Tranchant C (2007) Epidemiologic studies of environmental exposures in Parkinson’s disease. J Neurol Sci 262:37–44PubMedCrossRefGoogle Scholar
  32. 32.
    Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62:353–357PubMedCrossRefGoogle Scholar
  33. 33.
    Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14PubMedGoogle Scholar
  34. 34.
    Fahn S, Elton RL (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DM, Lieberman A (eds) Recent development in Parkinson’s disease. MacMillan Health Care Information, Florham Park, NJ, pp 153–163Google Scholar
  35. 35.
    Fenelon G (2008) Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13:18–25PubMedGoogle Scholar
  36. 36.
    Fenelon G, Goetz CG, Karenberg A (2006) Hallucinations in Parkinson disease in the prelevodopa era. Neurology 66:93–98PubMedCrossRefGoogle Scholar
  37. 37.
    Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733–745PubMedCrossRefGoogle Scholar
  38. 38.
    Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, Holmes J, Kingdom WK, MacMahon DG, Peto V, Playfer JR (2003) Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord 18:1139–1145PubMedCrossRefGoogle Scholar
  39. 39.
    Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 127:550–560PubMedCrossRefGoogle Scholar
  40. 40.
    Gagnon JF, Bedard MA, Fantini ML, Petit D, Panisset M, Rompre S, Carrier J, Montplaisir J (2002) REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology 59:585–589PubMedGoogle Scholar
  41. 41.
    Gandhi S, Wood NW (2005) Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet 14:2749–2755CrossRefGoogle Scholar
  42. 42.
    Garber CE, Friedman JH (2003) Effects of fatigue on physical activity and function in patients with Parkinson’s disease. Neurology 60:1119–1124PubMedCrossRefGoogle Scholar
  43. 43.
    Garcia-Borreguero D, Larrosa O, Bravo M (2003) Parkinson’s disease and sleep. Sleep Med Rev 7:115–129PubMedCrossRefGoogle Scholar
  44. 44.
    Vazquez A, Sanchez Bernardos V, Vazquez A (2004) Motor complications in Parkinson disease: a prospective follow-up study. Clin Neuropharmacol 27:49–52PubMedCrossRefGoogle Scholar
  45. 45.
    Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznai B, Fabrizio E, Vieregge P, Horstmann RD (1998) A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nat Genet 18:262–265PubMedCrossRefGoogle Scholar
  46. 46.
    Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39PubMedCrossRefGoogle Scholar
  47. 47.
    Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C (2001) Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56:1712–1721PubMedGoogle Scholar
  48. 48.
    Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2006) Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 67:853–858PubMedCrossRefGoogle Scholar
  49. 49.
    Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP (2008) Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson’s disease over time. J Neurol Neurosurg Psychiatry 79:387–391PubMedCrossRefGoogle Scholar
  50. 50.
    Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP (2007) Insomnia in Parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry 78:476–479PubMedCrossRefGoogle Scholar
  51. 51.
    Gjerstad MD, Aarsland D, Larsen JP (2002) Development of daytime somnolence over time in Parkinson’s disease. Neurology 58:1544–1546PubMedGoogle Scholar
  52. 52.
    Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB (2001) Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 57:2078–2082PubMedGoogle Scholar
  53. 53.
    Goetz CG, Tanner CM, Stebbins GT, Buchman AS (1988) Risk factors for progression in Parkinson’s disease. Neurology 38:1841–1844PubMedGoogle Scholar
  54. 54.
    Grimbergen YA, Munneke M, Bloem BR (2004) Falls in Parkinson’s disease. Curr Opin Neurol 17:405–415PubMedCrossRefGoogle Scholar
  55. 55.
    Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22:839–842PubMedCrossRefGoogle Scholar
  56. 56.
    Hagell P, Nordling S, Reimer J, Grabowski M, Persson U (2002) Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Mov Disord 17:1213–1220PubMedCrossRefGoogle Scholar
  57. 57.
    Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70:1456–1460PubMedCrossRefGoogle Scholar
  58. 58.
    Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63:1756–1760PubMedCrossRefGoogle Scholar
  59. 59.
    Hely MA, Morris JG, Reid WG, O’Sullivan DJ, Williamson PM, Broe GA, Adena MA (1995) Age at onset: the major determinant of outcome in Parkinson’s disease. Acta Neurol Scand 92:455–463PubMedCrossRefGoogle Scholar
  60. 60.
    Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20:190–199PubMedCrossRefGoogle Scholar
  61. 61.
    Herlofson K, Larsen JP (2003) The influence of fatigue on health-related quality of life in patients with Parkinson’s disease. Acta Neurol Scand 107:1–6PubMedCrossRefGoogle Scholar
  62. 62.
    Herlofson K, Lie SA, Arsland D, Larsen JP (2004) Mortality and Parkinson disease: A community based study. Neurology 62:937–942PubMedGoogle Scholar
  63. 63.
    Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, Rudolf J, Herholz K, Heiss WD (2005) Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62:378–382PubMedCrossRefGoogle Scholar
  64. 64.
    Hoehn M, Yahr M (1967) Parkinsonism: Onset, progression, and mortality. Neurology 17:427–442PubMedCrossRefGoogle Scholar
  65. 65.
    Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17:427–442PubMedCrossRefGoogle Scholar
  66. 66.
    Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70:734–738PubMedCrossRefGoogle Scholar
  67. 67.
    Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathologic study. Neurology 42:1142–1146PubMedGoogle Scholar
  68. 68.
    Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870PubMedCrossRefGoogle Scholar
  69. 69.
    Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 50:140–148PubMedGoogle Scholar
  70. 70.
    Hughes AJ, Daniel SE, Lees AJ (1993) The clinical features of Parkinson’s disease in 100 histologically proven cases. Adv Neurol 60:595–599PubMedGoogle Scholar
  71. 71.
    Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57:1497–1499PubMedGoogle Scholar
  72. 72.
    Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54:1596–1602PubMedGoogle Scholar
  73. 73.
    Hui JS, Murdock GA, Chung JS, Lew MF (2005) Behavioral changes as side effects of medication treatment for Parkinson’s disease. Adv Neurol 96:114–129PubMedGoogle Scholar
  74. 74.
    Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I (2002) Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov Disord 17:366–371PubMedCrossRefGoogle Scholar
  75. 75.
    Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, et al. (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40:1529–1534PubMedGoogle Scholar
  76. 76.
    Janvin C, Aarsland D, Larsen JP, Hugdahl K (2003) Neuropsychological profile of patients with Parkinson’s disease without dementia. Dement Geriatr Cogn Disord 15:126–131PubMedCrossRefGoogle Scholar
  77. 77.
    Kandinov B, Giladi N, Korczyn AD (2007) The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson’s disease. Parkinsonism Relat Disord 13:243–245PubMedCrossRefGoogle Scholar
  78. 78.
    Karlsen KH, Larsen JP, Tandberg E, Maeland JG (1999) Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:431–435PubMedGoogle Scholar
  79. 79.
    Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ (2004) Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1749–1752PubMedCrossRefGoogle Scholar
  80. 80.
    Keranen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, Kola H, Ylikoski A, Satomaa O, Kovanen J, Taimela E, Haapaniemi H, Turunen H, Takala A (2003) Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 9:163–168PubMedCrossRefGoogle Scholar
  81. 81.
    Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608PubMedCrossRefGoogle Scholar
  82. 82.
    Koller WC, Hutton JT, Tolosa E, Capilldeo R (1999) Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53:1012–1019PubMedGoogle Scholar
  83. 83.
    Korchounov A, Kessler KR, Yakhno NN, Damulin IV, Schipper HI (2005) Determinants of autonomic dysfunction in idiopathic Parkinson’s disease. J Neurol 252:1530–1536PubMedCrossRefGoogle Scholar
  84. 84.
    Krishnan PR, Bhatia M, Behari M (2003) Restless legs syndrome in Parkinson’s disease: a case-controlled study. Mov Disord 18:181–185PubMedCrossRefGoogle Scholar
  85. 85.
    Kurz M, Alves G, Aarsland D, Larsen JP (2003) Familial Parkinson’s disease: a community-based study. Eur J Neurol 10:159–163PubMedCrossRefGoogle Scholar
  86. 86.
    Lai BC, Marion SA, Teschke K, Tsui JK (2002) Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord 8:297–309PubMedCrossRefGoogle Scholar
  87. 87.
    Larsen JP, Karlsen K, Tandberg E (2000) Clinical problems in non-fluctuating patients with Parkinson’s disease: a community-based study. Mov Disord 15:826–829PubMedCrossRefGoogle Scholar
  88. 88.
    Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18:414–418PubMedCrossRefGoogle Scholar
  89. 89.
    Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH (1998) Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson’s disease. Hum Genet 103:424–427PubMedCrossRefGoogle Scholar
  90. 90.
    Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002) Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 51:722–729PubMedCrossRefGoogle Scholar
  91. 91.
    Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K (2000) Motor impairment in PD: relationship to incident dementia and age. Neurology 55:539–544PubMedGoogle Scholar
  92. 92.
    Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, Stern Y, Marder K (2002) The association of incident dementia with mortality in PD. Neurology 59:1708–1713PubMedGoogle Scholar
  93. 93.
    Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I (1998) Apathy is not depression. J Neuropsychiatry Clin Neurosci 10:314–319PubMedGoogle Scholar
  94. 94.
    Litvan I (1998) Parkinsonian features: when are they Parkinson disease? Jama 280:1654–1655PubMedCrossRefGoogle Scholar
  95. 95.
    Loo HV, Tan EK (2008) Case-control study of restless legs syndrome and quality of sleep in Parkinson’s disease. J Neurol Sci 266:145–149PubMedCrossRefGoogle Scholar
  96. 96.
    Lou JS, Kearns G, Oken B, Sexton G, Nutt J (2001) Exacerbated physical fatigue and mental fatigue in Parkinson’s disease. Mov Disord 16:190–196PubMedCrossRefGoogle Scholar
  97. 97.
    Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K (1999) Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56:334–337PubMedCrossRefGoogle Scholar
  98. 98.
    Lu J, Jhou TC, Saper CB (2006) Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 26:193–202PubMedCrossRefGoogle Scholar
  99. 99.
    Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 52:695–701PubMedGoogle Scholar
  100. 100.
    Marin RS (1991) Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 3:243–254PubMedGoogle Scholar
  101. 101.
    Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE (2005) Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 64:87–93PubMedGoogle Scholar
  102. 102.
    Marras C, Rochon P, Lang AE (2002) Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 59:1724–1728PubMedCrossRefGoogle Scholar
  103. 103.
    McKeith IG (2006) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 9:417–423PubMedGoogle Scholar
  104. 104.
    Meara J, Bhowmick BK, Hobson P (1999) Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing 28:99–102PubMedCrossRefGoogle Scholar
  105. 105.
    Mesholam RI, Moberg PJ, Mahr RN, Doty RL (1998) Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol 55:84–90PubMedCrossRefGoogle Scholar
  106. 106.
    Mizuno S, Miyaoka T, Inagaki T, Horiguchi J (2005) Prevalence of restless legs syndrome in non-institutionalized Japanese elderly. Psychiatry Clin Neurosci 59:461–465PubMedCrossRefGoogle Scholar
  107. 107.
    Mjones H (1949) Paralysis agitans: a clinical and genetic study. Acta Psychiatr Neurol Scand 54(Suppl):1–195Google Scholar
  108. 108.
    Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P (1997) Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 12:61–65PubMedCrossRefGoogle Scholar
  109. 109.
    Morrish PK (2003) How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson’s disease? Mov Disord 18(Suppl 7):S63–S70PubMedCrossRefGoogle Scholar
  110. 110.
    Morrish PK, Sawle GV, Brooks DJ (1996) An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 119(Pt 2):585–591PubMedCrossRefGoogle Scholar
  111. 111.
    Muller A, Reichmann H, Livermore A, Hummel T (2002) Olfactory function in idiopathic Parkinson’s disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 109:805–811PubMedCrossRefGoogle Scholar
  112. 112.
    Muller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I (2000) Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 55:888–891PubMedGoogle Scholar
  113. 113.
    Myslobodsky M, Lalonde FM, Hicks L (2001) Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol 14:120–124PubMedCrossRefGoogle Scholar
  114. 114.
    Nilsson FM, Kessing LV, Bolwig TG (2001) Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 104:380–386PubMedCrossRefGoogle Scholar
  115. 115.
    Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG (2002) Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 106:202–211PubMedCrossRefGoogle Scholar
  116. 116.
    Nomura T, Inoue Y, Miyake M, Yasui K, Nakashima K (2006) Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson’s disease. Mov Disord 21:380–384PubMedCrossRefGoogle Scholar
  117. 117.
    Oka H, Mochio S, Onouchi K, Morita M, Yoshioka M, Inoue K (2006) Cardiovascular dysautonomia in de novo Parkinson’s disease. J Neurol Sci 241:59–65PubMedCrossRefGoogle Scholar
  118. 118.
    Olanow CW (2007) The pathogenesis of cell death in Parkinson’s disease – 2007. Mov Disord 22(Suppl 17):S335–S342CrossRefPubMedGoogle Scholar
  119. 119.
    Olanow CW, Schapira AH, Roth T (2000) Waking up to sleep episodes in Parkinson’s disease. Mov Disord 15:212–215PubMedCrossRefGoogle Scholar
  120. 120.
    Ondo WG, Vuong KD, Jankovic J (2002) Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59:421–424PubMedCrossRefGoogle Scholar
  121. 121.
    Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44:595–600PubMedCrossRefGoogle Scholar
  122. 122.
    Patel V, Kirkwood BR, Weiss H, Pednekar S, Fernandes J, Pereira B, Upadhye M, Mabey D (2005) Chronic fatigue in developing countries: population based survey of women in India. BMJ 330:1190PubMedCrossRefGoogle Scholar
  123. 123.
    Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, Edwardson JA, Ince P, Blessed G, Irving D, et al. (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci 640:197–202PubMedGoogle Scholar
  124. 124.
    Pickering RM, Grimbergen YA, Rigney U, Ashburn A, Mazibrada G, Wood B, Gray P, Kerr G, Bloem BR (2007) A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord 22:1892–1900PubMedCrossRefGoogle Scholar
  125. 125.
    Pluck GC, Brown RG (2002) Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 73:636–642PubMedCrossRefGoogle Scholar
  126. 126.
    Poewe WH, Wenning GK (1998) The natural history of Parkinson’s disease. Ann Neurol 44:S1–S9PubMedCrossRefGoogle Scholar
  127. 127.
    Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181PubMedCrossRefGoogle Scholar
  128. 128.
    Post B, Merkus MP, de Haan RJ, Speelman JD (2007) Prognostic factors for the progression of Parkinson’s disease: a systematic review. Mov Disord 22:1839–1851; quiz 1988PubMedCrossRefGoogle Scholar
  129. 129.
    Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ (2002) Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 17:867–876PubMedCrossRefGoogle Scholar
  130. 130.
    Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061–1068PubMedCrossRefGoogle Scholar
  131. 131.
    Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189; quiz 313PubMedCrossRefGoogle Scholar
  132. 132.
    Rippon GA, Marder KS (2005) Dementia in Parkinson’s disease. Adv Neurol 96:95–113PubMedGoogle Scholar
  133. 133.
    Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63:167–173PubMedCrossRefGoogle Scholar
  134. 134.
    Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K (2000) Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 54:1064–1068PubMedGoogle Scholar
  135. 135.
    Rye DB, Bliwise DL, Dihenia B, Gurecki P (2000) FAST TRACK: daytime sleepiness in Parkinson’s disease. J Sleep Res 9:63–69PubMedCrossRefGoogle Scholar
  136. 136.
    Saper CB, Scammell TE, Lu J (2005) Hypothalamic regulation of sleep and circadian rhythms. Nature 437:1257–1263PubMedCrossRefGoogle Scholar
  137. 137.
    Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W (2007) Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 22:1229–1238PubMedCrossRefGoogle Scholar
  138. 138.
    Schrag A, Ben-Shlomo Y, Quinn N (2002) How common are complications of Parkinson’s disease? J Neurol 249:419–423PubMedCrossRefGoogle Scholar
  139. 139.
    Schrag A, Ben-Shlomo Y, Quinn N (2002) How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry 73:529–534PubMedCrossRefGoogle Scholar
  140. 140.
    Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP (2007) Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 22:938–945PubMedCrossRefGoogle Scholar
  141. 141.
    Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69:308–312PubMedCrossRefGoogle Scholar
  142. 142.
    Seppi K, Schocke MF (2005) An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 18:370–375PubMedCrossRefGoogle Scholar
  143. 143.
    Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2000) Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 15:669–677PubMedCrossRefGoogle Scholar
  144. 144.
    Shulman LM (2007) Gender differences in Parkinson’s disease. Gend Med 4:8–18PubMedCrossRefGoogle Scholar
  145. 145.
    Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 16:507–510PubMedCrossRefGoogle Scholar
  146. 146.
    Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19:1196–1202PubMedCrossRefGoogle Scholar
  147. 147.
    Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R (2005) Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics 23:817–836PubMedCrossRefGoogle Scholar
  148. 148.
    Stenager EN, Wermuth L, Stenager E, Boldsen J (1994) Suicide in patients with Parkinson’s disease. An epidemiological study. Acta Psychiatr Scand 90:70–72PubMedCrossRefGoogle Scholar
  149. 149.
    Stolze H, Klebe S, Zechlin C, Baecker C, Friege L, Deuschl G (2004) Falls in frequent neurological diseases – prevalence, risk factors and aetiology. J Neurol 251:79–84PubMedCrossRefGoogle Scholar
  150. 150.
    Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ (2006) Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:968–975PubMedCrossRefGoogle Scholar
  151. 151.
    Tan EK (2006) Restless legs syndrome and Parkinson’s disease: is there an etiologic link? J Neurol 253(Suppl 7):VII33–VII37PubMedCrossRefGoogle Scholar
  152. 152.
    Tan EK, Seah A, See SJ, Lim E, Wong MC, Koh KK (2001) Restless legs syndrome in an Asian population: A study in Singapore. Mov Disord 16:577–579PubMedCrossRefGoogle Scholar
  153. 153.
    Tandberg E, Larsen JP, Karlsen K (1998) A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord 13:895–899PubMedCrossRefGoogle Scholar
  154. 154.
    Tandberg E, Larsen JP, Aarsland D, Cummings JL (1996) The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol 53:175–179PubMedGoogle Scholar
  155. 155.
    Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL (1997) Risk factors for depression in Parkinson disease. Arch Neurol 54:625–630PubMedGoogle Scholar
  156. 156.
    Tanner CM, Aston DA (2000) Epidemiology of Parkinson’s disease and akinetic syndromes. Curr Opin Neurol 13:427–430PubMedCrossRefGoogle Scholar
  157. 157.
    Taylor KS, Cook JA, Counsell CE (2007) Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry 78:905–906PubMedCrossRefGoogle Scholar
  158. 158.
    Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519–522PubMedCrossRefGoogle Scholar
  159. 159.
    Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Hasnaoui A (2005) Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 65:239–246PubMedCrossRefGoogle Scholar
  160. 160.
    Tolosa E, Compta Y, Gaig C (2007) The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 13(Suppl):S2–S7PubMedCrossRefGoogle Scholar
  161. 161.
    Twelves D, Perkins KS, Counsell C (2003) Systematic review of incidence studies of Parkinson’s disease. Mov Disord 18:19–31PubMedCrossRefGoogle Scholar
  162. 162.
    Uitti RJ, Baba Y, Wszolek ZK, Putzke DJ (2005) Defining the Parkinson’s disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. Parkinsonism Relat Disord 11:139–145PubMedCrossRefGoogle Scholar
  163. 163.
    Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35–p36. Am J Hum Genet 68:895–900PubMedCrossRefGoogle Scholar
  164. 164.
    Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022PubMedCrossRefGoogle Scholar
  165. 165.
    van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers L, Breedveld GJ, Horstink M, Sandkuijl LA, van Swieten JC, Oostra BA, Heutink P (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69:629–634PubMedCrossRefGoogle Scholar
  166. 166.
    Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ (2007) Patient-reported autonomic symptoms in Parkinson disease. Neurology 69:333–341PubMedCrossRefGoogle Scholar
  167. 167.
    Verhagen L (2006) Depression in Parkinson’s disease: epidemiology and clinical features. In: Woltes EC, Berendse HW, Stam CJ (eds) Mental dysfunction in Parkinson’s disease III. VU University Press, Amsterdam, pp 176–188Google Scholar
  168. 168.
    von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 15:473–490PubMedCrossRefGoogle Scholar
  169. 169.
    White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, Rodriguez BL, Blanchette PL, Havlik RJ, Wergowske G, Chiu D, Foley DJ, Murdaugh C, Curb JD (1996) Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. Jama 276:955–960PubMedCrossRefGoogle Scholar
  170. 170.
    Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798PubMedCrossRefGoogle Scholar
  171. 171.
    Williams DR, Watt HC, Lees AJ (2006) Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 77:468–473PubMedCrossRefGoogle Scholar
  172. 172.
    Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA (2002) Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 59:408–413PubMedGoogle Scholar
  173. 173.
    Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607PubMedCrossRefGoogle Scholar
  174. 174.
    Aarsland D, Alves G, Larsen JP (2005) Disorders of motivation, sexual conduct, and sleep in Parkinson’s disease. Adv Neurol 96:56–64PubMedGoogle Scholar
  175. 175.
    Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392PubMedCrossRefGoogle Scholar
  176. 176.
    Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56:730–736PubMedGoogle Scholar
  177. 177.
    Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, Kragh-Sorensen P (2004) The rate of cognitive decline in Parkinson disease. Arch Neurol 61:1906–1911PubMedCrossRefGoogle Scholar
  178. 178.
    Aarsland D, Kvaloy JT, Andersen K, Larsen JP, Tang MX, Lolk A, Kragh-Sorensen P, Marder K (2007) The effect of age of onset of PD on risk of dementia. J Neurol 254:38–45PubMedCrossRefGoogle Scholar
  179. 179.
    Aarsland D, Larsen JP, Cummins JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56:595–601PubMedCrossRefGoogle Scholar
  180. 180.
    Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL (1999) Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:492–496PubMedGoogle Scholar
  181. 181.
    Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 48:938–942PubMedGoogle Scholar
  182. 182.
    Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M (2005) Clinical features of LRRK2-associated Parkinson’s disease in central Norway. Ann Neurol 57:762–765PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Guido Alves
    • 1
    • 3
  • Elin Bjelland Forsaa
    • 1
    • 3
  • Kenn Freddy Pedersen
    • 1
    • 3
  • Michaela Dreetz Gjerstad
    • 1
    • 3
  • Jan Petter Larsen
    • 1
    • 2
    • 3
  1. 1.The Norwegian Centre for Movement DisordersStavanger University HospitalStavangerNorway
  2. 2.Institute of Clinical Medicine, School of MedicineUniversity of BergenBergenNorway
  3. 3.Dept. of NeurologyStavanger University HospitalStavangerNorway

Personalised recommendations